MO38-2 Safety and pharmacokinetics (PK) of tusamitamab ravtansine (tusa) in Japanese patients (pts) with advanced solid tumors

Kentaro Yamazaki,Takayuki Yoshino,Kazunori Honda,Yasutoshi Kuboki,Takeshi Kawakami,Seiichiro Mitani,Yoshiaki Nakamura,Hiroya Taniguchi,Hideaki Bando,Tomoyuki Tanaka,Keisuke Tada,Nathalie Fagniez,Kei Muro

doi:10.1016/j.annonc.2022.05.198

MO38-2 Safety and pharmacokinetics (PK) of tusamitamab ravtansine (tusa) in Japanese patients (pts) with advanced solid tumors

Kentaro Yamazaki, Takayuki Yoshino + Show 11 more

Open Access

https://doi.org/10.1016/j.annonc.2022.05.198

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Jul 1, 2022
License type: publisher-specific-oa

Affiliation: National Cancer Center Hospital East, Aichi Cancer Center

#Carcinoembryonic Antigen-related Cell Adhesion Molecule #Maximum Tolerated Dose + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Tusa is an antibody-drug conjugate that targets carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)-expressing tumors. The maximum tolerated dose (MTD) of tusa was defined as 100 mg/m2 every 2 weeks in the global study. This phase 1 dose escalation study (NCT03324113) aimed to evaluate safety of tusa in Japanese pts.

Full Text